Alain Micaleff
Impact in
- Pharmacology top 5%
- Drug-Induced Hepatotoxicity and Protection
- Pharmacogenetics and Drug Metabolism
- Toxicology top 10%
- Pharmacovigilance and Adverse Drug Reactions
Papers in
-
- Health Systems, Economic Evaluations, Quality of Life 4
- Pharmaceutical Economics and Policy 2
-
- Pharmacovigilance and Adverse Drug Reactions 2
- Co-authors
- Dominique Larrey (1 shared paper)G Babany (1 shared paper)J P Benhamou (1 shared paper)M Morichau-Beauchant (1 shared paper)Thierry Vial (1 shared paper)H Michel (1 shared paper)Deborah Ashby (7 shared papers)Shahrul Mt‐Isa (7 shared papers)
- Journals
- Pharmacoepidemiology and Drug Safety (3 papers)Therapeutic Innovation & Regulatory Science (1 paper)Drug Discovery Today Technologies (1 paper)Drug Safety (1 paper)Clinical Pharmacology & Therapeutics (1 paper)
- Partner nations
- SwitzerlandUnited KingdomUnited States
In The Last Decade
Alain Micaleff
13 papers receiving 410 citations
Peers
Comparison fields: 5 of 66
- Pharmacology 114
- Toxicology 31
- Statistics and Probability 41
- Hepatology 34
- Economics and Econometrics 94
Countries citing papers authored by Alain Micaleff
This map shows the geographic impact of Alain Micaleff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain Micaleff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain Micaleff more than expected).
Fields of papers citing papers by Alain Micaleff
This network shows the impact of papers produced by Alain Micaleff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain Micaleff. The network helps show where Alain Micaleff may publish in the future.
Co-authors
The 25 scholars most cited alongside Alain Micaleff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1992 | 118 | |
| 2 | 2014 | 90 | |
| 3 | 2003 | 68 | |
| 4 | 2016 | 57 | |
| 5 | 2015 | 34 | |
| 6 | 2015 | 19 | |
| 7 | IMI-PROTECT benefit-risk grouprecommendations report:recommendations for the methodology andvisualisation techniques to be used in theassessment of benefit and risk of medicines | 2014 | 13 |
| 8 | 2016 | 7 | |
| 9 | 2011 | 6 | |
| 10 | [Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary]. | 1997 | 5 |
| 11 | IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab) | 2013 | 4 |
| 12 | Review of visualisation methods for therepresentation of benefit-risk assessment ofmedication: stage 2 of 2 | 2013 | 4 |
| 13 | IMI work package 5: report 2:b:ii benefit - riskwave 2 case study report: Rosiglitazone | 2013 | 2 |
About Alain Micaleff
Alain Micaleff is a scholar working on Economics and Econometrics, Toxicology, Pharmacology, Pharmacology and Pathology and Forensic Medicine, having authored 13 papers that have together received 427 indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (4 papers), Pharmaceutical Economics and Policy (2 papers), Pharmacovigilance and Adverse Drug Reactions (2 papers), Pharmaceutical industry and healthcare (1 paper), Multiple Sclerosis Research Studies (1 paper), Hepatitis B Virus Studies (1 paper), Biosimilars and Bioanalytical Methods (1 paper) and Drug-Induced Hepatotoxicity and Protection (1 paper). The work is most often cited by research in Pharmacology (114 citations), Toxicology (31 citations), Statistics and Probability (41 citations), Hepatology (34 citations) and Economics and Econometrics (94 citations). Alain Micaleff has collaborated with scholars based in Switzerland, United Kingdom and United States. Frequent co-authors include Dominique Larrey, G Babany, J P Benhamou, M Morichau-Beauchant, Thierry Vial, H Michel, Deborah Ashby, Shahrul Mt‐Isa, Lawrence D. Phillips and Christine E. Hallgreen. Their work appears in journals such as Pharmacoepidemiology and Drug Safety, Therapeutic Innovation & Regulatory Science, Drug Discovery Today Technologies, Drug Safety and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.